Radioiodine Therapy of Hyperthyroidism (Toxic Goiter, Hyperfunctioning Nodule) and Non-Toxic Goiter: Procedures and Guidelines

Part of the Medical Radiology book series (MEDRAD)


The purpose of the present chapter on the radioiodine-131 (I-131) therapy of benign thyroid disorders is to provide advice to nuclear medicine clinicians on how to treat toxic goiter, hyperfunctioning nodules and non-toxic goiter employing optimal I-131 activities. For this purpose, recommendations have been formulated based on the EANM procedure guidelines, recent literature and expert opinion regarding indications for I-131 therapy and alternative treatment modalities, as well as the adequate radioiodine activities in different thyroid disorders and the administration and patient preparation techniques to be used. Recommendations also are provided on pretherapeutic “radioiodine testing”. Furthermore, potential adverse effects are reviewed. The main side-effect of radioiodine treatment is hypothyroidism and levothyroxine medication is needed in all patients with elevated TSH after I-131 therapy.


Multinodular Goiter Thyroid Volume Antithyroid Drug Radioiodine Therapy Radioiodine Treatment 





Antithyroid drug


Fine needle aspiration biopsy


Free levothyroxine in serum


Free triiodothyronine in serum


Iodine-131 (radioiodine)


Levothyroxine medication




Recombinant human TSH


Standard deviation




Thyroidal peroxidase




  1. Bachmann J, Kobe C, Bor S, Rahlff I, Dietlein M, Schicha H, Schmidt M (2009) Radioiodine therapy for thyroid volume reduction of large goiters. Nucl Med Commun 30:466–471PubMedCrossRefGoogle Scholar
  2. Bal CS, Kumar A, Pandey RM (2002) A randomized controlled trial to evaluate the adjuvant effect of lithium on radioiodine treatment of hyperthyroidism. Thyroid 12:399–405PubMedCrossRefGoogle Scholar
  3. Bockisch A, Jamitzky T, Derwanz R, Biersack HJ (1993) Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med 34:1632–1638PubMedGoogle Scholar
  4. Boeleart K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC, Franklyn JA (2009) Prediction of cure and risk of hypothyroidism in patients receiving I-131 for hyperthyroidism. Clin Endocrinol 70:129–138CrossRefGoogle Scholar
  5. Bogazzi F, Bartalena L, Brogioni S, Scarcello G, Burelli A, Compomori A, Manetti L, Rossi G, Pinchera A, Martino E (1999) Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves’ hyperthyroidism. J Clin Endocrinol Metab 84:499–530PubMedGoogle Scholar
  6. Boice Jr JD (2005) Radiation induced thyroid cancer—what’s new? J Natl Cancer Inst 97:703–705PubMedCrossRefGoogle Scholar
  7. Bonnema SJ, Andersen PB, Knudsen DU, Hegedus L (2002) MR Imaging of large multinodular goiters: observer agreement on volume versus observer disagreement on dimension of the involved trachea. Am J Roentgenol 179:259–266CrossRefGoogle Scholar
  8. Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L (2004) Propylthiouracil before I-131 therapy of hyperthyroid diseases; effect on cure rate evaluated by a randomized clinical trial. J Clin Endocrinol Metab 89:4439–4444PubMedCrossRefGoogle Scholar
  9. Bonnema SJ, Nielsen VE, Boel-Jørgensen H, Grupe P, Andersen PB, Bastholt L, Hegedus L (2007) Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab 92:3424–3434PubMedCrossRefGoogle Scholar
  10. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS (2002) The effect of methimazole on cure rates after radioiodine treatment for Graves’ hyperthyroidism: a randomized clinical trial. Thyroid 12:135–139PubMedCrossRefGoogle Scholar
  11. Brunn J, Block U, Ruf G, Bos I, Kunze WP, Schriba PC (1981) Volumetric analysis of thyroid lobes by real-time ultrasound. Dtsch Med Wschr 106:1338–1340PubMedCrossRefGoogle Scholar
  12. Cappelen T, Unhjem JF, Amundsen AL, Kravdal G, Følling I (2006) Radiation exposure to family members of patients with thyrotoxicosis treated with iodine-131. Eur J Nucl Med Mol Imaging 33:81–86PubMedCrossRefGoogle Scholar
  13. Col NF, Surks MI, Daniels GH (2004) Subclinical thyroid disease. Clinical applications. JAMA 291:239–243PubMedCrossRefGoogle Scholar
  14. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214PubMedCrossRefGoogle Scholar
  15. de Rooy A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM (2009) Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol 161:771–777CrossRefGoogle Scholar
  16. Dickman PW, Holm LE, Lundell G, Boice JD Jr, Hall P (2003) Thyroid cancer risk after thyroid examination with I-131: a population-based cohort study in Sweden. Int J Cancer 106:580–587PubMedCrossRefGoogle Scholar
  17. Dietlein M, Dressler J, Eschner W, Lassman M, Leisner B, Reiners C, Schicha H (2007a) Procedure guideline for radioiodine test (version 3). Nuklearmedizin 46:198–202PubMedGoogle Scholar
  18. Dietlein M, Dressler J, Grünwald F, Leisner B, Moser E, Reiners C, Schicha H, Schneider P, Schober O (2007b) Guideline for radioiodine therapy for benign thyroid diseases (version 4). Nuklearmedizin 46:220–223PubMedGoogle Scholar
  19. Dillehay GL, Ellerbroek NA, Balon H, Brill DR, Grigsby PW, Macklis RM, Mauch PM, Mian TA, Potters L, Silberstein EB, Williams TR, Wong JC, Gaspar LE (2006) American society for therapeutic radiology and oncology. Practice guideline for the performance of therapy with unsealed radiopharmaceutical sources. Int J Radiat Oncol Biol Phys 64:1299–1307PubMedCrossRefGoogle Scholar
  20. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV (1974) Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 38:976–998PubMedCrossRefGoogle Scholar
  21. Dunkelmann S, Endlicher D, Prillwitz A, Rudolph F, Groth P, Schuemichen C (1999) Results of a TcTUs-optimized radioiodine therapy of multifocal and disseminated functional thyroid autonomy. Nuklearmedizin 38:131–139PubMedGoogle Scholar
  22. Eskes SA, Wiersinga WM (2009) Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab 23:735–751PubMedCrossRefGoogle Scholar
  23. Fast S, Nielsen V, Bonnema S, Hegedus L (2008) Time to reconsider nonsurgical therapy of benign nontoxic multinodular goiter. Focus on recombinant human TSH (rhTSH) augmented radioiodine therapy. Eur J Endocrinol 160:517–528PubMedCrossRefGoogle Scholar
  24. Fast S, Nielsen VE, Grupe P, Bonnema SJ, Hegedus L (2009) Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med 50:732–737PubMedCrossRefGoogle Scholar
  25. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population based cohort study. Lancet 353:2111–2115PubMedCrossRefGoogle Scholar
  26. Freitas JE (2000) Therapeutic options in the management of toxic and nontoxic nodular goiter. Semin Nucl Med 30:88–97PubMedCrossRefGoogle Scholar
  27. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FDR, Wilson S, Sheppard MC, Franklyn JA (2007) Association between serum free thyroxine concentration and atrial fibrillation. Arch Intern Med 167:928–934PubMedCrossRefGoogle Scholar
  28. Hall P, Holm LE (1997) Late consequences of radioiodine for diagnosis and therapy in Sweden. Thyroid 7:205–208PubMedCrossRefGoogle Scholar
  29. Hall P, Lundell G, Holm LE (1993) Mortality in patients treated for hyperthyroidism with iodine-131. Acta Endocrinol (Cph) 128:230–234Google Scholar
  30. Heeringa J, Hoogendoorn EH, van der Deure WM, Hofman A, Peeters RP, Hop CJ, den Heijer M, Visser TJ, Witteman JCM (2008) High-normal thyroid function and risk of atrial fibrillation—the Rotterdam study. Arch Intern Med 168:2219–2224PubMedCrossRefGoogle Scholar
  31. Hegedus L, Bonnema SJ, Bennedbaek FN (2003) Management of simple nodular goiter: current status and future perspectives. Endocr Rev 24:102–132PubMedCrossRefGoogle Scholar
  32. International Commission on Radiological Protection (2004) Release of patients after therapy with unsealed radionuclides. Ann ICRP 34:1–79. Erratum in: Ann ICRP 34(3–4): 281Google Scholar
  33. Kaptein EM, Levenson H, Siege ME, Gadallah M, Akmal M (2000) Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. J Clin Endocrinol Metab 85:3058–3064PubMedGoogle Scholar
  34. Kobe C, Weber I, Eschner W, Sudbrock F, Schmidt M, Dietlein M, Schicha H (2008a) Graves’ disease and radioiodine therapy: is success of ablation dependent on the choice of thyreostatic medication? Nuklearmedizin 47:153–166PubMedGoogle Scholar
  35. Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, Schicha H (2008b) Graves’ disease and radioiodine therapy: is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin 47:13–17PubMedGoogle Scholar
  36. Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, Dietlein M, Schicha H (2010) Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of I-131? Nucl Med Commun 31:201–205PubMedCrossRefGoogle Scholar
  37. Koch W, Rosa F, Knesewitsch P, Hahn K (2005) Guideline on radiation protection in medicine requires documentation of radioiodine therapy and follow-up: what are the benefits of an electronic database? Nuklearmedizin 44:49–55PubMedGoogle Scholar
  38. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA (2003) A randomized comparison of radioiodine in Graves’ hyperthyroidism. J Clin Endocrinol Metab 88:978–983PubMedCrossRefGoogle Scholar
  39. Lucignani G (2007) Long-term risks in hyperthyroid patients treated with radioiodine: is there anything new? Eur J Nucl Med Mol Imaging 34:1504–1509PubMedCrossRefGoogle Scholar
  40. Manders JMB, Corstens FHM (2002) Radioiodine therapy of euthyroid multinodular goiters. Eur J Nucl Med 29(Suppl 2):S466–S470CrossRefGoogle Scholar
  41. Marinelli LD, Quimby EH, Hine G (1950) Dosimetry of radioactive isotopes; biological observations and practical applications. Strahlentherapie 81:587–594PubMedGoogle Scholar
  42. McDermott MT, Woodmansee WW, Haugen BR, Smart A, Ridgway EC (2003) The management of subclinical hyperthyroidism by thyroid specialists. Thyroid 13:1133–1139PubMedCrossRefGoogle Scholar
  43. Moka D, Dietlein M, Schicha H (2002) Radioiodine therapy and thyrostatic drugs and iodine. Eur J Nucl Med Mol Imaging 29(Suppl 2):S486–S491PubMedCrossRefGoogle Scholar
  44. Moschetta M, Ianora AA, Testini M, Vacca M, Scardapane A, Angelelli G (2010) Multidetector computed tomography in the preoperative evaluation of retrosternal goiters: a useful procedure for patients for whom magnetic resonance imaging is contraindicated. Thyroid 20:181–187PubMedCrossRefGoogle Scholar
  45. Nielsen VE, Bonnema SJ, Hegedus L (2006a) Transient goiter enlargement after administration of 0.3 mg of recombinant human thyrotropin in patients with benign non-toxic nodular goiter: a randomized, double-blind, cross-over trial. J Clin Endocrinol Metab 91:1317–1322PubMedCrossRefGoogle Scholar
  46. Nielsen VE, Bonnema SJ, Boel-Jorgensen H, Grupe P, Hegedus L (2006b) Stimulation with 0.3 mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign non-toxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med 166:1476–1482PubMedCrossRefGoogle Scholar
  47. Nieuwlaat WA, Huysmans DA, van den Bosch HC, Sweep CG, Ross HA, Corstens FH, Hermus AR (2003) Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab 88:3121–3129PubMedCrossRefGoogle Scholar
  48. Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, Crescenzi A, Nardi F, Fabbrini R, Pacella CM (1998) Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. J Clin Endocrinol Metab 83:780–783PubMedCrossRefGoogle Scholar
  49. Reiners C, Schneider P (2002) Radioiodine therapy of thyroid autonomy. Eur J Nucl Med 29(Suppl 2):S471–S478CrossRefGoogle Scholar
  50. Reinhardt MJ, Joe A, von Mallek D, Zimmerlin M, Manka-Waluch A, Palmedo H, Krause TM (2002) Dose selection for radioiodine therapy of borderline hyperthyroid patients with multifocal and disseminated autonomy on the basis of 99mTc-pertechnetate thyroid uptake. Eur J Nucl Med Mol Imaging 29:480–485PubMedCrossRefGoogle Scholar
  51. Reinhardt MJ, Kim B, Wissmeyer M, Juengling F, Brockmann H, von Mallek D, Ezziddin S, Joe AY, Krause T (2006) Dose selection for radioiodine therapy of borderline hyperthyroid patients according to thyroid uptake of 99mTc-pertechnetate: applicability to unifocal thyroid autonomy? Eur J Nucl Med Mol Imaging 33:608–612PubMedCrossRefGoogle Scholar
  52. Salvatori M, Luster M (2010) Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 37:821–828PubMedCrossRefGoogle Scholar
  53. Santos RB, Romaldini JH, Ward LS (2004) Propylthiouracil reduces the effectiveness of radioiodine treatment in hyperthyroid patients with Graves’ disease. Thyroid 14:525–530PubMedCrossRefGoogle Scholar
  54. Schmidt M, Gorbauch E, Dietlein M, Faust M, Stützer H, Eschner W, Theissen P, Schicha H (2006) Incidence of postradioiodine immunogenic hyperthyroidism/Graves′ disease in relation to a temporary increase in thyrotropin receptor antibodies after radioiodine therapy for autonomous thyroid disease. Thyroid 16:281–288PubMedCrossRefGoogle Scholar
  55. Silva MN, Rubió IG, Romão R, Gebrin EM, Buchpiguel C, Tomimori E, Camargo R, Cardia MS, Medeiros-Neto G (2004) Administration of a single dose of recombinant human thyrotrophin enhances the efficacy of radioiodine treatment of large compressive multinodular goiters. Clin Endocrinol (Oxf) 60:300–308CrossRefGoogle Scholar
  56. Sisson JC, Avram AM, Rubello Gross MD (2007) Radioiodine treatment of hyperthyroidism: fixed or calculated doses; intelligent design of science? Eur J Nucl Med Mol Imaging 34:1129–1130PubMedCrossRefGoogle Scholar
  57. Stabin MG, Brill AB (2008) State of the art in nuclear medicine dose assessment. Semin Nucl Med 38:308–320PubMedCrossRefGoogle Scholar
  58. Stokkel M, Handkiewicz J, Lassmann M, Dietlein M, Luster M (2010) EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging 37:2218–2228PubMedCrossRefGoogle Scholar
  59. Surks MI, Ortiz E, Daniels GH et al (2004) Subclinical thyroid disease. Scientific review and guidelines for diagnosis and management. JAMA 291:229–238CrossRefGoogle Scholar
  60. Walter MA, Crist-Crain M, Schindler C, Mueller-Brand J, Mueller B (2006) Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. Eur J Nucl Med Mol Imaging 33:730–737PubMedCrossRefGoogle Scholar
  61. Weetman AP (2007) Radioiodine treatment for benign thyroid diseases. Clin Endocrinol 66:757–764CrossRefGoogle Scholar
  62. Wesche MF, Tiel-V Buul MM, Lips P, Smits NJ, Wiersinga WM (2001) A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab 86:998–1005PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  1. 1.Department of Nuclear MedicineUniversity Hospital of CologneCologneGermany

Personalised recommendations